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Abstract
The pandemic caused by the novel coronavirus
SARS-CoV-2 has placed an unprecedented burden on
healthcare systems around the world. In patients who
experience severe disease, acute respiratory distress is
often accompanied by a pathological immune reaction,
sometimes referred to as ‘cytokine storm’. One hallmark
feature of the profound inflammatory state seen in
patients with COVID-19 who succumb to pneumonia
and hypoxia is marked elevation of serum cytokines,
especially interferon gamma, tumor necrosis factor alpha,
interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6
(IL-6). Initial experience from the outbreaks in Italy, China
and the USA has anecdotally demonstrated improved
outcomes for critically ill patients with COVID-19 with the
administration of cytokine-modulatory therapies, especially
anti-IL-6 agents. Although ongoing trials are investigating
anti-IL-6 therapies, access to these therapies is a
concern, especially as the numbers of cases worldwide
continue to climb. An immunology-informed approach
may help identify alternative agents to modulate the
pathological inflammation seen in patients with COVID-19.
Drawing on extensive experience administering these
and other immune-modulating therapies, the Society
for Immunotherapy of Cancer offers this perspective
on potential alternatives to anti-IL-6 that may also
warrant consideration for management of the systemic
inflammatory response and pulmonary compromise that
can be seen in patients with severe COVID-19.

Introduction
Coronaviruses are a family of enveloped,
positive sense, single-strand RNA viruses that
infect mammals and birds. In humans, coronavirus infections typically cause mild respiratory disease, including seasonal colds, yet
some members of the family can be highly
virulent. In December 2019, a novel coronavirus, SARS-CoV-2, structurally related to
the virus that causes severe acute respiratory
syndrome (SARS) and Middle East respiratory
syndrome (MERS), was identified in Wuhan,
China. Its efficient transmission (R0 of 2.2)

facilitated its spread across the globe, with
the first detected case in the USA reported on
January 19, 2020.1 On March 11, 2020, WHO
declared the outbreak a pandemic.2
The ongoing COVID-19 outbreak is challenging every aspect of daily life, including
the implementation of public health policy,
the nature of social interactions, adaptation
of the workforce to a ‘new normal’ and the
medical research and clinical care infrastructure, including the care for oncology
patients. Economic forecasts are concerning,
and a global financial crisis is anticipated.
Mathematical modeling based on available
data shows that in the face of rapid geographical spread and a high case-fatality ratio, even
the most advanced healthcare systems are
very likely to be overwhelmed in the coming
weeks and months.3 It will be critical to identify therapies with low barriers to rapid clinical deployment.
It is becoming apparent that in some
patients, severe COVID-19 disease occurs, and
is accompanied by a fulminant and damaging
immune reaction, sometimes called the ‘cytokine storm’, characterized by pronounced
infiltration of macrophages and monocytes into the alveolae, a pro-
inflammatory
T-helper 17 (Th17) response, and elevated
levels of inflammatory cytokines, particularly
IL-6, IL-1β, IL-8, interferon gamma (IFNγ)
and tumor necrosis factor alpha (TNFα).4–7
This pro-
inflammatory cytokine profile has
been with poor prognosis and severe lung
pathology characterized by interstitial mononuclear inflammatory infiltrates, diffuse alveolar damage, hyaline membrane formation
and pulmonary edema.8–10
As the oncology community rallies
behind our colleagues in intensive care,
internal medicine, emergency medicine and
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Rationale for targeting IL-6
SARS-
CoV-2 causes the emergent respiratory disease
called COVID-19. One of the challenging aspects in
management of the infection is that different presentations have been identified16:
►► Asymptomatic carrier state
►► Mild
respiratory
symptoms,
not
requiring
hospitalization
►► Recovered and re-examined positive for SARS-CoV-2
nucleic acid after discharge
►► Acute respiratory disease: respiratory presentation
(fever, cough, dyspnea), without radiological evidence
of a parenchymal process. Additional symptoms may
include myalgias, headache, sore throat, anosmia,
chills, diarrhea, nausea and vomiting.
►► Severe respiratory disease: pneumonia, often bilateral,
which can progress in severity ultimately requiring
mechanical ventilation and intensive care management. While ARDS is the common feature in patients
with severe disease, other manifestations have been
described, such as acute cardiac injury, acute kidney
injury, coagulopathy and shock.17
►► Lethal infection: the case-
fatality rate has been
reported from 0.1% to 2%, although complete
2

epidemiological analysis is ongoing worldwide and
facing the challenge of testing availability. Death is
typically due to massive alveolar damage and irreversible respiratory failure.18
Almost 75% of patients with COVID-19 acute respiratory disease present with abnormal findings on chest
CT scans. Ground-glass opacities are the most common
finding, reported in as many as 60% of patients. Other
findings include patchy infiltrates, and interstitial lung
disease, although some patients present with minimal
imaging abnormalities.5 7 17 19
Pathological findings resemble those seen in SARS and
MERS: edema, proteinaceous exudates, focal reactive
pneumocyte type II hyperplasia, patchy cellular inflammation and multinucleated giant cells.9 Notably, neutrophil infiltration is not significant.20
Elevated C reactive protein (CRP) and elevated aspartate transaminase are common in patients with COVID-19
and reports from Hubei province in China indicate that
severe cases are associated with elevated levels of inflammatory markers including serum d-dimer, ferritin and
lactate dehydrogenase.21 The cytokine profile of severe
COVID-19 disease is characterized by elevated IL-2, IL-6,
IL-7, IL-8, granulocyte-colony stimulating factor, IL-17,
TNFα and other markers that indicate systemic inflammatory response,22 similar to what has been described
in macrophage activation syndrome (MAS) or in
hemophagocytic lymphohistiocytosis (HLH).23 24 Moreover, a retrospective multicenter study of 150 patients
performed from Wuhan, China suggested that among
other clinical parameters, CRP and IL-6 levels can be
predictors of mortality. Among 68 patients who died,
median IL-6 level was 11.4 ng/mL as opposed to 6.8 ng/
mL in those 82 who survived (p<0.001).25 Additionally, an
elevated neutrophil-to-leukocyte ratio was also predictive
of poor prognosis.
In the USA, anticipated shortages of key resources
including intensive care unit (ICU) beds and mechanical ventilators has led to the implementation of social
distancing measures to avoid overloading a medical system
that is not prepared to care for an overwhelming number
of affected individuals.26 While a concerted effort to
increase and coordinate the supply of personal protective
equipment for healthcare workers as well as mechanical
ventilators for patient care is clearly needed,27 a complementary approach to decrease the number of patients
with severe disease, and/or decrease the time required in
the ICU on a ventilator is important as well.
Based on emerging information as centers gain more
experience treating SARS-CoV-2-infected patients, modulating or inhibiting the IL-6 signaling pathway to mitigate
the inflammatory response related to COVID-19 is an
attractive idea.15 There is a successful precedent for this
strategy, as it is almost routinely considered in patients
receiving T cell engaging therapies, such as CAR T cells
or blinatumomab. In these contexts, IL-6 levels peak at
the time of maximal T cell proliferation and patients
may develop a CRS that can be quite severe and even
Arnaldez FI, et al. J Immunother Cancer 2020;8:e000930. doi:10.1136/jitc-2020-000930
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infectious disease, the immunotherapy field is poised to
offer insights into the application of immune-modulatory
therapies. Modulation of IL-6, in particular, which has
emerged as a potentially promising option for COVID19-related acute respiratory distress syndrome (ARDS),
is used for the treatment of some rheumatological disorders,11 and has become a mainstay in recent years in the
management of cytokine release syndrome (CRS) after
chimeric antigen receptor (CAR) T cell therapy for hematological malignancies.12–14 Although the cytokine levels
observed in patients with COVID-19 experiencing ARDS
are much lower than those seen in CRS after delivery
of CAR Tcell therapies and CD3-based bispecific Tcell
engagers, the cancer immunotherapy community’s experience in using the IL-6 receptor antagonists to modulate
severe inflammatory pathology in the setting of CRS may
prove to be useful in identifying therapies that could be
of use in this setting.
Healthcare and research organizations continue to
aggressively pursue development of a vaccines and effective therapeutic strategies to attenuate the burden of
SAR-
CoV-2 (including antimalarial, antimicrobial and
directed antiviral agents as well as convalescent serum
from patients who have cleared virus and recovered)
and to support patients through the severe inflammatory response and pulmonary complications that can
frequently occur. The aim of this analysis is to describe
available strategies that could alleviate the burden on the
healthcare system with a specific emphasis on therapeutics that could block or modulate the systemic inflammatory response and pulmonary complications caused by
COVID-19, in particular, IL-6, IL-1 and TNFα pathways.15
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ideally before symptoms start to rapidly deteriorate at
the onset of the cytokine storm. It is critical to observe
high-risk cases, patients with persistent fever, diffuse lung
opacities on CT scans and elevated serum CRP and IL-6
(if cytokine measurements are available). Because the
condition can quickly change from mild to severe, early
intervention should be strongly considered.
While establishing new indications for an agent generally requires evaluation in a rigorous, often randomized
clinical trial, the massive impact of this pandemic, and the
lack of any existing standard-of-care might provide appropriate context to consider off-label use of IL-6 inhibition
for severely ill patients affected by COVID-19. China’s
National Health Commission has recently issued updated
treatment guidelines that include the use of tocilizumab
in patients with severe disease.34
The FDA is closely monitoring the medical product
supply chain,35 and the demand for drugs used to treat
patients with COVID-19 including but not limited to
tocilizumab, could surpass the ability to manufacture
these agents. Additionally, in some cases, access to tocilizumab and sarilumab is limited despite adequate supply.
For example, the study protocol for sarilumab in COVID19-related ARDS initially excluded individuals who have
recently been treated with any other investigational drugs,
high-dose steroids or cyclophosphamide chemotherapy—
effectively preventing numerous patients with cancer and
patients receiving immunotherapy from receiving this
potentially lifesaving intervention—however, amended
exclusion criteria may relax these requirements. Ongoing
and future clinical trials should consider the unique characteristics of oncology patients in their design (including
inclusion and exclusion criteria), in light of the fact that
the large, immune-suppressed population of patients with
cancer may be particularly susceptible to severe complications of COVID-19.36 In addition, although data are not
available, it is unknown whether pulmonary manifestations of COVID-19 may be potentiated or attenuated in
oncology patients being treated with immunotherapeutic
approaches that themselves can have significant pulmonary toxicity, including checkpoint inhibitors and CAR T
cells.
Although tocilizumab and sarilumab are presently
the most well-studied anti-IL-6 agents in the COVID-19
setting, numerous agents have been developed to modulate pro-inflammatory signaling at multiple levels in the
pathway. An immunology-informed approach could identify potential alternatives to tocilizumab and sarilumab,
broadening the population of patients that may receive
treatment to ameliorate the complications of COVID19, and thus ‘flattening the curve’ for total patient days
requiring ICU support, including mechanical ventilation.
Overview of IL-6 signaling and regulation
IL-6 is a pleiotropic cytokine with nearly ubiquitous expression in stromal and immune cells. In the airway, alveolar macrophages produce IL-6, and expression may be
3

J Immunother Cancer: first published as 10.1136/jitc-2020-000930 on 7 May 2020. Downloaded from http://jitc.bmj.com/ on May 8, 2020 by guest. Protected by copyright.

life-threatening.14 Administration of IL-6 blocking agents
such as tocilizumab and siltuximab has been shown to be
effective in reversing CRS in these patients.28–30 Tocilizumab was approved by the Food and Drug Administration (FDA) for the treatment of CRS secondary to CAR T
cell therapy in 2017,13 and incorporated into the risk evaluation and mitigation strategies for the approved CAR T
cell therapy products, tisagenlecleucel and axicabtagene
ciloleucel.
A word of caution should be exercised in extrapolating
the adoptive cell transfer experience using IL-6 inhibition
to COVID-19, as formal comparative analysis of the levels
of pro-inflammatory cytokines in both situations has not
yet been performed. Initial data from the COVID-19
pandemic indicate that cytokine levels are far lower in the
context of SARS-CoV-2 infection than seen in CRS.25 31
A 21-
patient observational study recently performed
in China supports the use of tocilizumab to avoid rapid
clinical deterioration of individuals with severe pneumonitis and pulmonary complications.32 Anecdotal cases
reported in Italy33 also point that tocilizumab may be clinically active in decreasing the magnitude of the inflammatory response associated with COVID-19, with rapid
improvements observed in critically ill patients, even those
requiring mechanical ventilation. On March 19, 2020,
the Italian Medicines Agency announced the launch of
TOCIVID-19, an independent phase II study to evaluate
the efficacy and safety of tocilizumab in the treatment of
pneumonia during COVID-19. Accrual of 330 patients
was reached within 24 hours. In the USA, a randomized,
double-blind, placebo-controlled phase III clinical trial
has recently been approved by the US FDA to evaluate
the efficacy of tocilizumab plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia
(NCT04320615). A randomized, placebo-
controlled
phase II/III study evaluating the efficacy of low-dose and
high-dose sarilumab, another IL-6-modulating therapy in
hospitalized patients with COVID-19 against placebo is
also ongoing (NCT04315298).
Multiple doses of tocilizumab may be necessary for
maximal benefit. In the Chinese study protocol, patients
received 400 mg once through an intravenous drip up to
a maximum of 800 mg with an optimal dose of 8 mg/kg
body weight. In cases of fever within 12 hours after the
first administration, an additional dose of up to the same
amount as the first would be given, with two doses as
the cumulative upper limit. The protocol for the Italian
trial, calls for doses comparable to those commonly used
for the management of CRS, namely, 8 mg/kg (up to a
maximum of 800 mg per dose), with a second administration of the same dose given after 12 hours if respiratory
function has not recovered, at discretion of the investigator. In preliminary reports from Italy, meaningful
effects have also been observed with the subcutaneous
formulation of tocilizumab.
A key lesson learned from the experience of treating
about 500 severe or critical patients in China is the necessity of starting tocilizumab therapy as soon as possible,
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Regulation of IL-6 expression
Expression of IL-6 is regulated at multiple levels including
chromatin accessibility, transcription, mRNA export,
post-transcription and translation. TNFα and IL-1β also
induce IL-6 expression.41 Coronavirus’ spike proteins
have also been shown to directly promote IL-6 production in immune and epithelial cells. Cultured SARS-CoV-
infected bronchial epithelial cells secrete IL-6,42 and
murine macrophages upregulate IL-6 and TNFα through
a nuclear factor-κB-dependent pathway in response to
viral S protein.43
IL-6 signaling (classical and trans)
Signaling through the IL-6 receptor requires assembly at
the cell membrane of a complex consisting of IL-6 bound
to both the 80 kDa type 1 cytokine a-receptor subunit (IL-
6R, also called CD126) and a 130 kDa signal-transducing
b-receptor glycoprotein (gp130; also called CD130). This
trimeric complex homodimerizes, leading to receptor
activation.11 44 Expression of the membrane-
bound
form of IL-6R is largely restricted to hepatocytes, megakaryocytes and leukocytes,45 yet two independent pathways generate a soluble form of the receptor: cleavage
by membrane metalloproteinases, primarily ADAM10
and ADAM17, as well as alternative splicing.45–47 Soluble
IL-6/IL-6R receptor complex can also bind gp130, activating the downstream signaling cascade. The ubiquitous expression of gp130, which has been detected in all
human tissues examined, underlies the pleiotropic effects
of IL-6, and the near universal responsiveness to the cytokine across cell types. Receptor activation through the
membrane-bound IL-6R versus the soluble form of IL-6R
are referred to as classical and trans signaling, respectively. Generally, classical signaling contributes to regenerative and anti-inflammatory responses, whereas trans
signaling is pro-inflammatory and plays a role in causing
tissue damage.
Signal transduction
Ligand binding at the IL-6R activates multiple intracellular signaling cascades, including Janus kinase (JAK)/
signal transducer and activation of transcription (STAT)
4

pathways and the phosphatidylinositol 3-kinase (PI3K)
pathway. Of potential importance in the context of
COVID-19, the activation of JAK1 and STAT3 kinases
by IL-
6R initiates a pro-
inflammatory transcriptional
program associated with proliferation, differentiation,
recruitment, survival and transformation in T and B
cells and myeloid cells.11 44 45 An overview of IL-6 signal
transduction with modes of action of approved IL-6-
modulatory therapies is illustrated in figure 1.

Potential therapeutic strategies
IL-6 blocking agents have been developed in the recent
years to treat rheumatological conditions. Tocilizumab
was approved by the FDA in 2010 to treat moderately to
severely active rheumatoid arthritis. While other indications followed, it was not until August 2017 that it received
approval for the treatment of CAR T cell-induced CRS.
Many other agents have since been developed or are
under investigation to modulate the circulating levels,
receptor binding and/or biological effects of IL-6. The
FDA-approved agents are listed in table 1, whereas therapies that are not yet approved, but are in later-stage clinical development are described in online supplementary
table 1. Caution should be exercised in attempting to
equate antireceptor and antiligand antibodies. The safety
and efficacy of some of these agents that have not yet
achieved regulatory approval has not been established.
Furthermore, none of the agents has achieved regulatory
approval for use in patients with COVID-19, although
China has issued treatment guidelines recommending
tocilizumab for severe SARS-CoV-2 pneumonia.
As with all immune-modulatory agents, patients treated
with anti-IL-6/IL-6R agents are at increased risk for infections, most commonly by opportunistic bacterial and
fungal pathogens. Patients with latent tuberculosis are at
risk of reactivation with IL-6 blockade. Other common
side effects that may be concern in the COVID-19 setting
include hypotension, decreased platelet counts, liver
toxicity, risk of gastrointestinal (GI) perforation and difficulty breathing.
Interleukin-6 antagonists
®
►► Tocilizumab (Actemra , Genentech) is an IL-
6R antagonist antibody also known as atlizumab. It is indicated
for the treatment of rheumatoid arthritis, giant cell
arteritis, polyarticular juvenile idiopathic arthritis,
systemic juvenile idiopathic arthritis and CAR-T cell-
induced severe CRS.
®
►► Sarilumab (Kevzara , Regeneron/Sanofi) is an IL-
6R
antagonist antibody indicated for the treatment of
adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response
or intolerance to one or more disease-modifying antirheumatic drugs.
►► Siltuximab (Sylvant™, EUSA Pharma) is an anti-IL-6 antibody, distinct from tocilizumab and sarilumab, as it
targets the soluble cytokine and not the receptor. It
Arnaldez FI, et al. J Immunother Cancer 2020;8:e000930. doi:10.1136/jitc-2020-000930

J Immunother Cancer: first published as 10.1136/jitc-2020-000930 on 7 May 2020. Downloaded from http://jitc.bmj.com/ on May 8, 2020 by guest. Protected by copyright.

induced in epithelial cells by IFNγ and danger-associated
molecular patterns (DAMPs).37 38 The effects of IL-6
are context-specific and may be both pro-inflammatory
and anti-
inflammatory. Although IL-6 is essential for
both innate and adaptive immunity—patients with auto-
antibodies to the cytokine or germline mutations in its
downstream signaling effectors are susceptible to recurrent infections and often die prematurely due to pneumonia. In turn, uncontrolled IL-6 expression leads to
profound inflammatory damage to host cells.11 39 Under
homeostatic conditions, serum concentrations of IL-6
are typically lower than picograms per mL, but under
conditions of severe inflammation, levels may reach up
to nanograms per mL, as seen in severe CRS31 or even
micrograms per mL in fatal sepsis.40
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is indicated for the treatment of patients with Castleman’s disease. Of note, it was not studied in patients
with HIV or human herpesvirus-8 (HHV-8) infections
as preclinical studies showed lack of binding to virally
produced IL-6. Therefore, it is only indicated in those
patients who are HIV and HHV-8 negative.
Janus kinase/signal transducer and activation of transcription
(JAK/STAT) inhibitors
While encouraging preliminary results have been
observed with IL-6 blockade, potential constraints on the
supply of IL-6/IL-6R-targeting antibodies may limit access
to these drugs and the numbers of patients that can
benefit. In order to expand the spectrum of patients who
may access IL-6-modulatory therapies, alternative targets
within the cytokine’s inflammatory signaling cascade
could be considered.
IL-6 signaling takes place via two mechanisms: binding
to a higher affinity membrane-bound receptor (classical)
or soluble IL-6 receptor (trans).41 44 Both lead to activation of JAK/STAT signaling downstream through JAK1
Arnaldez FI, et al. J Immunother Cancer 2020;8:e000930. doi:10.1136/jitc-2020-000930

and STAT3, on tyrosine phosphorylation on the gp130
receptor’s cytoplasmic tail. JAK/STAT signaling is also
activated by other pro-inflammatory cytokines that are
observed to be elevated in COVID-19, particularly IFNγ
(although IFN signaling is primarily via STAT1). STATs
also play important roles in non-canonical cell signaling
pathways, including activity of non-tyrosine phosphorylated STATs, mediation of DNA methylation, regulation
of cell adhesion and mitochondrial activity.48
Small molecules targeting this pathway have been
successfully introduced into the clinic, and are a therapeutic option in a number of inflammatory processes,49
including graft versus host disease and HLH.50 51 In
xenograft models, ruxolitinib was able to prevent CRS
after CAR Tcell therapy.52 Importantly, a phase III trial
is being initiated to assess ruxolitinib in combination
with standard of care compared with standard of care
alone in patients with severe COVID-19 pneumonia as a
result of SARS-CoV-2 infection.53 Additionally, a phase II
single-arm study of fedratinib is planned.
5
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Figure 1 Interleukin 6 (IL-6) signaling cascade. Antibodies such as tocilizumab, sarilumab and siltuximab inhibit IL-6 signaling
by antagonizing ligand-receptor engagement, whereas Jakinibs prevent the downstream signaling cascade. The intracellular
domain of gp130 is constitutively associated with the Janus family tyrosine kinases JAK1 and JAK2. On homodimerization,
JAKs autophosphorylate and JAK1 phosphorylates 5 tyrosine residues in the cytoplasmic tail of gp130, leading to the activation
of multiple intracellular signaling cascades. Recruitment and phosphorylation of STAT3 initiates its homodimerization and
nuclear trafficking, initiating a transcriptional program associated with proliferation, differentiation, recruitment, survival and
transformation in T and B cells and myeloid cells. A negative feedback loop modulates activation of the IL-6-JAK/STAT cascade,
as STAT3 upregulates SOCS1 and SOCS3, which directly inhibits the catalytic activity of JAK by binding to phosphorylated
gp130 at tyrosine 759, and stops JAK activation through direct binding.11 Phosphorylated gp130 is also a binding site for
SH2 domain tyrosine phosphatase 2 (SHP2), activating a cascade involving RAS, RAF and mitogen-activated protein kinases
(MAPK), which culminates in the activation of various transcription factors involved in increasing cell growth, antibody synthesis
and acute phase protein generation. JAK also phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2), which is then
phosphorylated by phosphoinositide 3-kinase (PI3K) to become phosphatidylinositol-3,4,5-trisphosphate (PIP3), which then
phosphorylates PkB/Akt serine/threonine kinase to modulate expression of several genes involved in cellular survival.12
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Agent

Mechanism of action

Commercial
name
Manufacturer
®

Indication(s)

Comments

Rheumatoid arthritis, giant
cell arteritis, polyarticular
juvenile idiopathic arthritis,
systemic juvenile idiopathic
arthritis, cytokine release
syndrome (Tcell induced)

Increases risk of
serious infections

Tocilizumab
Recombinant
humanized
monoclonal antibody
(IgG1)

Binds to both soluble
and membrane-bound
IL-6 receptors, and
inhibits IL-6-mediated
signaling

Actemra

Sarilumab
Human recombinant
monoclonal antibody
(IgG1)

Binds to both soluble
and membrane-bound
IL-6 receptors, and
inhibits IL-6-mediated
signaling

Kevzara®

Regeneron/Sanofi Moderately to severely
Increases risk of
active rheumatoid arthritis
serious infections
adults who have inadequate
response to disease-
modifying antirheumatic
drugs

Siltuximab
Glycosylated human-
mouse chimeric
monoclonal antibody
(IgG1)

Binds to soluble IL-6
and prevents the
binding to both soluble
and membrane-bound
IL-6 receptors

Sylvant™

Janssen/EUSA
Pharma UK

Genentech

Multicentric Castleman’s
disease

No binding to HHV-8
and HIV produced
IL-6 in a preclinical
study

HHV-8, human herpesvirus-8; IL, interleukin.

The rationale for developing these agents as an option
to prevent or treat cytokine release in COVID-19 is
compelling, especially given the relative ease of manufacturing small molecules at scale as compared with
biologics. The safety profiles of JAK inhibitors are generally manageable and predictable including increased risk
of viral infections, lower GI complications and anemia and
leukopenia.54 55 Because IL-6 signaling primarily occurs
through JAK1, the selectivity of JAK inhibitors should be
considered before their use for COVID-19. Additionally,
‘Jakinibs’ are oral tyrosine kinase inhibitors,54 which may
not be easily administered/absorbed in patients with very
severe ongoing systemic inflammatory response.
®
►► Ruxolitinib (Jakavi/Jakafi , Incyte) is an oral JAK inhibitor with selectivity for JAK1 and JAK2 indicated for
treatment of intermedia-
risk or high-
risk myelofibrosis, polycythemia vera unresponsive or intolerant
to hydroxyurea and steroid-
refractory graft versus
host disease in adult and pediatric patients aged 12
years and older.
®
►► Tofacitinib (Xeljanz , Jakvinus, Pfizer) is an oral JAK
inhibitor with selectivity for JAK1 and JAK3 indicated
for the treatment of rheumatoid arthritis, psoriatic
arthritis and ulcerative colitis. The occurrence of
serious infections and lymphoid-associated malignancies have led to a current black box warning imposed
by the FDA.
®
►► Baricitinib (Olumiant , Eli-Lilly) is an oral JAK inhibitor with specificity for JAK1 and JAK2 indicated for
the treatment of adult patients with moderately to
severely active rheumatoid arthritis who have had an
inadequate response to one or more TNF antagonist therapies. The occurrence of serious infections,
lymphoma and thrombosis have led to a current black
box warning imposed by the FDA.
6

►►

►►

►►

Peficitinib (Smyraf®, Astellas) is an oral pan-JAK inhibitor with JAK1, JAK2, JAK3 and tyrosine kinase 2
activity approved only in Japan and indicated for the
treatment of rheumatoid arthritis in patients who
have inadequate response to conventional therapies.
Upadacitinib (Rinvoq™, AbbVie) is a second-generation
oral JAK inhibitor with high specificity for JAK1 that
is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who
have had an inadequate response or intolerance to
methotrexate. The occurrence of serious infections,
lymphoma and thrombosis has led to a current black
box warning imposed by the FDA.
Fedratanib (Inrebic®, Impact Biomedicines/Celgene) is an
oral semi-selective JAK2 JAK inhibitor indicated for
the treatment of adult patients with intermediate or
high-
risk primary or secondary (postpolycythemia
vera or postessential thrombocythemia) myelofibrosis.
The occurrence of serious and fatal encephalopathy,
including Wernicke’s, has led to a black box warning
imposed by the FDA.

Interleukin-1 inhibitors
Modulation of IL-1 signaling, especially through the IL-1β
isoform, could also potentially attenuate the exuberant
inflammatory response that accompanies lung pathology
in COVID-19 upstream of IL-6. Although serum IL-1 has
CoV-2
not necessarily correlated with severity of SARS-
disease in published reports, its function as a master
cytokine elicits large effects with small perturbations.56–58
IL-1 signaling orchestrates the acute phase of response to
infections and has also been demonstrated to influence
the differentiation of lymphocytes, particularly Th17 cells.
Of the two isoforms, IL-1β is predominantly associated
with pulmonary pathology in ARDS.59 60 Although data
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Table 1 Food and Drug Administration-approved agents: IL-6
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inhibitor emapalumab for severe ARDS in COVID-19
(NCT04324021).
The overall safety profile of anti-IL-1 therapies is acceptable. As with any cytokine modulator, IL-1 blockade carries
increased risk of bacterial infections, but after many years
of clinical experience and tens of thousands of patients
treated, it has become apparent that opportunistic
infections are highly rare with anakinra treatment, even
among people at high risk for tuberculosis reactivation.
Of note, anti-IL-1 therapy is associated with a reduction
in circulating neutrophil counts,58 which may be clinically
significant given that a high NLR (Neutrophil to Leukocyte Ratio) is predictive of poor prognosis in COVID-19.
Evidence for improved outcomes after using IL-1 modulating therapies for CRS is lacking and variable. The
timing of IL-R1 antagonist administration may be critical,
and limited benefit may be obtained with treatment of
already-established ARDS. Targeting IL-1β directly, either
by reducing its effective concentration via a receptor trap
or monoclonal antibody may also be impactful.
®
►► Anakinra (Kinaret , Sobi) is a modified, recombinant
human IL-1R antagonist indicated for the treatment
of adult rheumatoid arthritis and neonatal-
onset
multisymptom inflammatory disease.
®
►► Rilonacept (Arcalyst , Regeneron) is a dimeric fusion
protein consisting of the extracellular domains
of IL-1R and IL-1RAcP, linked by the Fc portion of
human anti-IL-1 IgG1 indicated for the treatment of
adults and children 12 years of age and older with
CAPS.
®
►► Canakinumab (Ilaris , Novartis) is a human monoclonal anti-IL-1β antibody indicated for the treatment
of periodic fever syndromes (including CAPS) and
systematic juvenile idiopathic arthritis.
Tumor necrosis factor alpha inhibitors
Ligands and receptors of the tumor necrosis factor superfamily play central roles in regulation of the immune
system and tissue homeostasis. Although TNF signaling is
vital for antipathogen immune responses and is protective
in a variety of viral infections including smallpox,73 West
Nile virus74 and influenza,75 elevated levels of TNFα have
been linked to pulmonary pathology in acute lung injury.
Elevated TNFα is observed in both plasma and bronchoalveolar lavage fluid in patients with ARDS, and expression
of the cytokine directly leads to increased endothelial
permeability along with impaired alveolar fluid clearance
due to downregulation of epithelial sodium channels.76 77
Elevated serum TNFα has been reported to correlate with
severe disease in COVID-19,8 and the SARS-CoV S protein
has been demonstrated to induce TNFα and IL-6 upregulation in murine macrophages.43
The primary sources of TNFα are stimulated monocytes, fibroblasts and endothelial cells, although macrophages, T cells, B lymphocytes, granulocytes, smooth
muscle cells, eosinophils, chondrocytes, osteoblasts and
mast cells all produce TNFα as well.77–79 TNFα is synthesized as a membrane-protein and cleaved by ADAM17 to
7
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on the immunopathology underlying ARDS in COVID-19
are lacking, a pro-inflammatory Th17 signature has been
observed in patients infected with SARS-CoV-261 as well as
in patients with MERS-CoV.62 Additionally, IL-1 has been
shown to be a key cytokine driving pro-
inflammatory
activity in bronchoalveolar lavage fluid of patients with
acute lung injury.60
The IL-1 family of cytokines are major regulators of the
acute phase response, functioning to control inflammatory reactions in response to PAMPs and DAMPs released
from damaged or infected cells.57 63 Hundreds of genes
are transcriptionally upregulated by IL-1 signaling,
including IL-6. IL-1-
modulating therapies have been
FDA approved for a number of indications, primarily for
auto-inflammatory diseases where the primary drivers of
pathology are innate immune cells rather than the T cell
and Bcell compartments.64 Three IL-1-modulating therapies have been approved by the FDA, and each agent
inhibits signaling through a distinct mechanism, which
may have important implications for their possible use in
treating COVID-19.
Multiple mechanisms modulate IL-1 signaling,
including the soluble IL-1 receptor antagonist (IL-1RA),
which is secreted by immune cells, epithelial cells and
adipocytes,65 and the decoy receptor IL-
1RII, which
exists in both membrane-bound and soluble forms and
scavenges IL-1β with high affinity.66 These endogenous
factors have formed the basis for several IL-1-targeting
therapeutics, including anakinra (a receptor antagonist)
and rilonacept (a receptor trap). Additionally, an anti-
IL-1β antibody, canakinumab, has been FDA approved
for a variety of auto-inflammatory diseases.
Anakinra is a recombinant form of IL-1RA that lacks
glycosylation and is modified with the addition of a
single methionine residue at the N-terminus. Although
several randomized trials failed to demonstrate statistically significant 28-
day survival benefits for IL-
1R
antagonist therapy for sepsis,67–69 a reanalysis showed
profoundly improved outcomes among the subset of
patients with disseminated intravascular coagulation
and hepatobiliary dysfunction, hallmarks of secondary
MAS.70 Anakinra has also proven effective and gained
FDA approval for the treatment of a variety of autoinflammatory disorders including CAPS as well as rheumatoid arthritis.56 63 Anakinra is short-acting, with a plasma
half-life of roughly 4–6 hours.71
Anecdotal evidence has emerged that anakinra effectively modulates late-
onset, tocilizumab-
refractory CRS
with clinical features similar to HLH/MAS secondary to
CAR T cell therapy.72 Initial experience from the Northern
Italian SARS-CoV-2 outbreak, however, has indicated that
anakinra monotherapy did not provide clinical benefit
when administered to patients with severe ARDS.33 It is
possible that multiple mechanisms need to be targeted,
as cytokine profiles from patients with COVID-19 demonstrate marked elevation of multiple factors beyond IL-1,
including IL-6, IL-17, TNFα and IFNγ. An ongoing clinical
trial is evaluating anakinra in combination with the IFNγ
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Interferon gamma
IFNγ is a pleiotropic cytokine that plays an essential
role in multiple phases of immune and inflammatory
responses. The IFN family of proteins encompasses three
distinct classes, with variable direct antiviral and immune-
modulatory activities.87 The IFNγ receptor is expressed
on both malignant and non-malignant cell populations.88
On receptor binding, IFNγ initiates a signaling cascade
through JAK1 and JAK2 activation, which leads to STAT1
homodimerization and nuclear translocation and transcriptional activation of a wide array of IFN-
inducible
genes through the GAS enhancer element.88 89 IFNγ has
been implicated as an important downstream effector
cytokine in the antitumor immune response, and in
the immune response to various infectious pathogens,
including viruses.90 Although protective in the context of
antiviral host defense, IFNγ also has been implicated in
the pathogenesis of ‘cytokine storm’ and in various autoimmune diseases.91 92 Anti-IFN therapy has been investigated in HLH, rheumatoid arthritis, multiple sclerosis,
Crohn’s disease and psoriasis.91 93
Elevated serum IFNγ has been associated with severe
acute respiratory distress in COVID-19.8 21 36 94 Additionally, IFNγ enhances IL-6 production in monocytes95 and
an IFNγ-related cytokine storm syndrome was reported
in some patients during the 2003 SARS coronavirus
outbreak.96 Anti-IFN antibodies have been demonstrated
to alleviate acute lung injury induced by severe H1N1
influenza infection in murine models,97 and a trial of the
human monoclonal anti-
IFNγ emapalumab in combination with the IL-1 receptor antagonist anakinra for
COVID-19 is ongoing.98
Anti-interferon therapy is approved in the US for the
treatment of primary HLH. In the pivotal trial for the
approval of emapalumab for HLH, the most commonly
reported adverse events included infections, hypertension, infusion reactions and fever.99
®
►► Emapalumab (Gamifant , Sobi) a human monoclonal
antibody that binds to soluble and receptor-bound
forms of IFNγ and is approved for the treatment of
primary HLH in patients with refractory, recurrent
or progressive disease or intolerance to conventional
therapy
Granulocyte macrophage-colony stimulating factor
Alveolar macrophages can play a central role in the
inflammatory pathology of ARDS through the release of a
wide array of bioactive factors that damage or induce cell
death in the lung epithelium such as proteases, reactive
oxygen species, eicosanoids, phospholipids and cytokines
including IL-1, IL-6 and TNFα.77 100 One key cytokine that
regulates macrophage number and function is granulocyte macrophage-colony stimulating factor (GM-CSF), a
monomeric glycoprotein secreted by macrophages, T
cells, mast cells, natural killer cells, endothelial cells and
fibroblasts. GM-CSF is upstream of IL-6 and induces an
inflammatory transcriptional program through JAK/
STAT signaling.101 Inactivation of GM-
CSF in CAR T
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release its soluble form. Both the soluble and membrane-
bound forms of TNFα are active, although their affinities to TNF-
family receptors varies. TNFα signaling is
complex, and may involve as many as 29 different tumor
necrosis factor receptor (TNFR) family members. In
particular, TNFR1 is widely expressed; as is the case for
IL-6 this broad-based expression gives rise to pleiotropic
systemic effects.
Multiple TNFα inhibitors have been developed for
the treatment of inflammatory diseases, and some have
demonstrated benefit in animal models of acute lung
injury and respiratory distress.80 These results have not
borne out in humans, however, as anti-
TNFα therapy
failed to protect patients from sepsis-induced acute lung
injury81 82 and did not improve outcomes for chronic
obstructive pulmonary disease.83 Preliminary reports
from China indicate that anti-
TNFα antibody offers
limited benefit for patients with SARS-
CoV-2 infections with established ARDS,84 although modulating
the pathway through other targets or at different timepoints may be more efficacious. In the oncology setting,
the anti-TNFα antibody infliximab is commonly used
for the management of immune-related adverse events
secondary to immune checkpoint inhibitor therapy.
Additionally, success has been reported with the use of
the TNFα receptor trap etanercept for the treatment of
CRS secondary to CAR T cell therapy85 and in MAS,86 but
no prospective, large-scale trials have demonstrated efficacy for TNF modulation in the setting of viral cytokine
storm. Adverse effects of concern for anti-TNFα therapy
include dampened cell-mediated immune responses. All
of the approved agents carry black box warning labels for
increased risk of serious, life-threatening opportunistic
bacterial and fungal infections and patients with latent
tuberculosis should not receive these therapies.
®
►► Infliximab (Remicade , Janssen) is a chimeric monoclonal anti-TNFα antibody indicated for the treatment of inflammatory bowel diseases in adults and
children, rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis.
®
►► Etanercept (Enbrel , Amgen) is a receptor trap consisting
of TNF-R2 fused to IgG1 Fc indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis.
®
►► Adalimumab (Humira , AbbVie) is a human monoclonal
anti-TNFα antibody indicated for the treatment of
rheumatoid arthritis, ankylosing spondylitis, Crohn’s
disease, psoriatic arthritis and plaque psoriasis.
®
►► Certulizumab pegol (Cimzia , UCB) is a human monoclonal anti-TNFα antibody conjugated to a 40 kDa
polyethylene glycol indicated for reducing signs and
symptoms in Crohn’s disease and the treatment of
rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
®
►► Golimumab (Simponi , Janssen) is a human monoclonal
anti-TNFα antibody indicated for the treatment of
rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis and Crohn’s disease.
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of otilimab, no serious adverse events and pulmonary
toxicity, including pulmonary alveolar proteinosis,
were observed.
Interleukin-17 and interleukin-23 inhibitors
IL-17 is a pro-
inflammatory cytokine. It is produced
by Th17 cells on stimulation with IL-23. The IL-17/
IL-23 axis stimulates the secretion of cytokines know
to mediate inflammation, including IL-6, and IL-6 (in
the presence of TGF-β) skews naïve CD4 T cells toward
the Th17 phenotype.108 IL-17/IL-23 signaling has been
postulated to mediate cross-talk between the innate and
the adaptive immune system.109 A characteristic Th17
signature has been noted in patients with COVID-19
ARDS,10 and modulation of IL-17 signaling through
the JAK/STAT inhibitor fedratinib has been proposed,
although this indication is currently speculative.61 Clinically, the use of agents that modulate this axis have
been mostly used in the treatment of chronic conditions
such as psoriasis109 and the most frequently observed
adverse events have been nasopharyngitis, upper respiratory tract inflammation and injection site reactions.110
Although these agents have the potential to dampen
IL-6 production and signaling, the use of IL-17/IL-23
modulators in conditions such as CRS has not yet been
widely tested.
®
►► Secukinumab (Cosentyx , Novartis) is a human IL-
17A
antagonist indicated for the treatment of moderate-
to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
®
►► Ixekizumab (Taltz , Eli-Lilly) is a humanized IL-
17A
antagonist indicated for the treatment of adults with
moderate-to-severe plaque psoriasis.
®
►► Brodalumab (Siliq , Valeant/LEO Pharma) is a human
IL-17 receptor A antagonist indicated for the treatment of moderate-
to-
severe plaque psoriasis. The
occurrence of suicidal ideation has led to a black box
warning imposed by the FDA.
®
►► Ustekinumab (Stelara , Janssen) is a human IL-12 and
IL-23 antagonist indicated for the treatment of adult
patients with moderate-
to-
severe plaque psoriasis,
active psoriatic arthritis and moderately to severely
active Crohn’s disease.
®
►► Guselkumab (Tremfya , Janssen) is an IL-23 blocker
indicated for the treatment of adult patients with
moderate-to-severe plaque psoriasis.
►► Tidrakizumab-asmn (Ilumya™, Sun Pharma Global) is an
IL-23 antagonist indicated for adults with moderate-
to-severe plaque psoriasis.
►► Risankizumab-r zaa (Skyrizi™, AbbVie) is an IL-23 antagonist indicated for the treatment of plaque psoriasis
Conclusion
The COVID-19 pandemic caused by SARS-CoV-2 highlights an urgent need for all healthcare stakeholders
including government organizations, academic centers,
community centers, philanthropic organizations, advocates, pharmaceutical and biotechnology industries to
9
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cells dramatically lowers IL-6 and IL-8 secretion102 and
therapeutic inhibition of GM-CSF reduces CAR T-cell-
associated CRS in mouse models.103
Initial evidence from a study of 52 patients with
COVID-19 reported from Wuhan, China, elevated levels
of circulating GM-CSF were associated with worse clinical
outcomes.18 22 Additionally, analysis of peripheral blood
samples from 33 patients with COVID-19 with pneumonia
found increased numbers of pathogenic Th1 cells (GM-
CSF+ IFNγ+) and inflammatory monocytes (CD14+ CD16+
with high expression of IL-6) in patients admitted to the
ICU as compared with non-critical patients.104 In early
April 2020, several studies evaluating anti-GM-CSF antibodies for COVID-19 treatment were initiated in rapid
succession, including trials of lenzilumab,105 TJM-2,106
gimsilumab107 and namilumab. One anti-GM-CSF antibody, lenzilumab, received emergency investigational
new drug approval for compassionate use in patients with
COVID-19. Although the safety profiles of anti-GM-CSF
antibodies have been acceptable in phase I and phase II
trials, it is important to note the potential for lung toxicities and pneumonia with these agents.101
►► Lenzilumab (Humanigen) is a human monoclonal
anti-
GM-
CSF antibody approved for compassionate
use in patients with COVID-19. A phase III trial for
COVID-19 is ongoing. Lenzilumab was originally
developed for the treatment of chronic myelomonocytic leukemia and has also been evaluated for inadequately controlled asthma and rheumatoid arthritis.
►► Namilumab (Izana Bioscience) is a human monoclonal
anti-
GM-
CSF antibody that has been evaluated in
phase II trials for plaque psoriasis and rheumatoid
arthritis. It is being evaluated in a two center compassionate use study for COVID-19 by UK-based Izana
Bioscience. In the rheumatoid arthritis study, a few
patients experienced AEs indicative of pulmonary
alveolar proteinosis, but following review all suggestive cases were given an alternative diagnosis.
►► Gimsilumab (Roivant) is a human monoclonal anti-
GM-CSF antibody developed for rheumatoid arthritis.
It has demonstrated favorable safety and tolerability
with no serious adverse events reported in two phase
I trials in healthy adult volunteers. Trials in patients
with COVID-19 will be prioritized instead of a planned
phase II study in patients with rheumatoid arthritis.
►► TJM-2 (I-
Mab Biopharma) is a neutralizing antibody
against GM-
CSF that is being developed to treat
cytokine storm in critically ill patients with COVID-19.
It previously exhibited favorable safety, tolerability,
pharmacokinetic/pharmacodynamic and immunogenicity profiles in a phase I dose-
escalation study
in the USA and received IND (Investigational New
Drug) clearance from China’s National Medical Products Administration for a multiple-dose phase Ib study
in patients with rheumatoid arthritis.
►► Otilimab (GSK) is a human GM-
CSF inhibitory antibody that started phase III evaluation for rheumatoid arthritis in July 2019. During the phase II trials
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develop a coordinated and flexible approach to increase
the availability of resources.
Modulation/inhibition of the severe inflammatory state
in patients with COVID-19, characterized by elaboration
of various inflammatory mediators, including IL-6, is a
potentially important strategy to treat and/or limit severe
COVID-19 pulmonary complications, including ARDS. If
successful across the broader population of patients with
COVID-19, strategies such as anti-IL-6-directed therapy
could reduce the needs for ICU support and mechanical
ventilation, and ultimately decrease mortality.
Randomized phase III trials are currently evaluating
the efficacy of anti-IL-6-directed agents, including tocilizumab and sarilumab, as well as the JAK/STAT inhibitor
ruxolitinib, and will provide definitive data regarding
the use of these agents in patients with COVID-19. As
described here, other anti-IL-6 agents, including small
molecule inhibitors of IL-6 signaling, and other anticytokine inhibitors may warrant investigation, particularly in
the setting of overwhelming demand for agents to modulate the inflammatory state in patients with COVID-19.
Ongoing studies are also investigating other strategies,
such as the use of eculizumab (a monoclonal antibody
that targets complement protein C5, approved for paroxysmal nocturnal hemoglobinuria), or some TLR7-8 inhibitors such as M5049. In all likelihood, a combinatorial
approach encompassing antivirals such as remdesivir and
potentially cytokine-modulatory therapies may be needed
to successfully treat the infection with SARS-CoV-2 and
the full spectrum of associated complications.
The US FDA has announced a new program, CTAP
(Coronavirus Treatment Acceleration Program), to
expedite drug development for COVID-19. While this is
encouraging news and the appropriate way to proceed
from a drug development perspective, the healthcare
community and, more importantly, the affected patients,
need effective treatments without delay, especially as the
numbers of cases in the USA and several countries around
the world continue to grow exponentially. Consideration
also should be given to focus efforts on rapidly expanding
the ability of clinicians and clinical investigators to access
investigational anti-
IL-6 agents, in particular for those
agents where phase II and/or phase II studies have been
completed, and acceptable safety has been demonstrated.
Use of cytokine-modulatory agents during these extreme
circumstances may additionally warrant consideration,
and definitive prospective randomized trials also should
be conducted with all due haste.
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